This biomarker is also known as:
- Pancreatic Secretory Trypsin Inhibitor,
- Serine Protease Inhibitor, Kazal Type 1,
- Serine Protease Inhibitor, Kazal-Type 1,
- Tumor-Associated Trypsin Inhibitor,
- Serine Peptidase Inhibitor, Kazal Type 1,
View in BioMuta
SPINK1 is a trypsin inhibitor, which is secreted from pancreatic acinar cells into pancreatic juice. Its physiological function is to prevent the trypsin-catalyzed premature activation of zymogens within the pancreas. Mutations in SPINK1 are associated with hereditary pancreatitis and tropical calcific pancreatitis.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
High levels of SPINK1 have been associated with a greater rate of prostate cancer recurrence.
Increased SPINK1 transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.